Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Memorial Sloan Kettering Cancer Center.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT00877110
First received: April 6, 2009
Last updated: February 4, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2016
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)